JPMorgan Chase & Co. decreased its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 19.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 569,529 shares of the medical instruments supplier’s stock after selling 140,598 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.96% of OraSure Technologies worth $12,951,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Fuller & Thaler Asset Management Inc. grew its holdings in OraSure Technologies by 175.6% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 898,397 shares of the medical instruments supplier’s stock valued at $20,214,000 after purchasing an additional 572,397 shares during the last quarter. Columbus Circle Investors boosted its position in OraSure Technologies by 56.0% in the 3rd quarter. Columbus Circle Investors now owns 527,511 shares of the medical instruments supplier’s stock valued at $11,869,000 after buying an additional 189,347 shares during the period. Cipher Capital LP purchased a new stake in OraSure Technologies in the 3rd quarter valued at about $1,333,000. Macquarie Group Ltd. boosted its position in OraSure Technologies by 89.9% in the 3rd quarter. Macquarie Group Ltd. now owns 98,200 shares of the medical instruments supplier’s stock valued at $2,210,000 after buying an additional 46,500 shares during the period. Finally, 361 Capital LLC lifted its position in shares of OraSure Technologies by 296.9% in the 3rd quarter. 361 Capital LLC now owns 107,066 shares of the medical instruments supplier’s stock worth $2,409,000 after purchasing an additional 80,092 shares during the period. Institutional investors own 94.43% of the company’s stock.
In other OraSure Technologies news, Director Mara G. Aspinall acquired 5,000 shares of the stock in a transaction dated Tuesday, November 7th. The stock was acquired at an average price of $14.23 per share, with a total value of $71,150.00. Following the completion of the purchase, the director now owns 5,000 shares in the company, valued at approximately $71,150. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 6.40% of the company’s stock.
OraSure Technologies, Inc. (OSUR) traded up $0.06 during trading hours on Friday, hitting $19.81. 352,845 shares of the stock traded hands, compared to its average volume of 582,522. OraSure Technologies, Inc. has a 12-month low of $8.39 and a 12-month high of $23.01. The stock has a market capitalization of $1,200.00, a P/E ratio of 38.10, a P/E/G ratio of 4.58 and a beta of 1.27.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business had revenue of $42.30 million during the quarter, compared to analysts’ expectations of $40.87 million. During the same period last year, the business earned $0.11 earnings per share. The business’s revenue for the quarter was up 31.0% on a year-over-year basis. analysts forecast that OraSure Technologies, Inc. will post 0.43 earnings per share for the current year.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Jefferies Group downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, Canaccord Genuity reissued a “buy” rating and set a $22.00 price target on shares of OraSure Technologies in a report on Tuesday, September 19th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. OraSure Technologies presently has a consensus rating of “Buy” and an average price target of $19.65.
ILLEGAL ACTIVITY WARNING: “JPMorgan Chase & Co. Sells 140,598 Shares of OraSure Technologies, Inc. (OSUR)” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://ledgergazette.com/2018/01/13/orasure-technologies-inc-osur-shares-sold-by-jpmorgan-chase-co.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.